GlassScriptPhysician profile
Mahsa Tehrani
NPI 1710113378
$18,864.10
in general payments reported to CMS, 2019-2025
38 companies · $1,901 in 2025
The $1,901 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,465 · 2020: $782 · 2021: $984 · 2022: $1,428 · 2023: $7,032 · 2024: $3,273 · 2025: $1,901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,107 · Consulting Fee: $3,800 · Travel and Lodging: $1,024 · Education: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,107.08 |
| Consulting Fee | $3,800.00 |
| Travel and Lodging | $1,023.94 |
| Education | $274.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $6,440.31 | 2019-2025 | Cosentyx |
| Abbvie INC. | $2,127.96 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $2,079.36 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $1,596.23 | 2019-2025 | Cimzia, Bimzelx |
| Amgen INC. | $1,587.48 | 2019-2025 | Tavneos, Enbrel, Krystexxa |
| Lilly USA, LLC | $545.72 | 2019-2024 | Taltz |
| Glaxosmithkline, LLC. | $523.73 | 2019-2025 | Benlysta, Nucala |
| Horizon Therapeutics Plc | $498.24 | 2019-2023 | Krystexxa, Tepezza |
| Mallinckrodt Hospital Products INC. | $437.12 | 2023-2025 | Acthar |
| Pfizer INC. | $398.51 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $372.11 | 2019-2025 | Orencia |
| Celgene Corporation | $271.33 | 2019 | |
| Aurinia Pharma U.S., INC. | $263.37 | 2021-2025 | Lupkynis |
| Genentech USA, INC. | $209.53 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $200.06 | 2021-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahsa Tehrani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.